{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:57:10Z","timestamp":1765486630598,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015613","name":"Centre hospitalier r\u00e9gional universitaire de Lille","doi-asserted-by":"publisher","award":["25000","66330"],"award-info":[{"award-number":["25000","66330"]}],"id":[{"id":"10.13039\/501100015613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ando.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T10:34:07Z","timestamp":1625913247000},"page":"582-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients)"],"prefix":"10.1016","volume":"82","author":[{"given":"Sara","family":"Barraud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Raingeard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Cortet-Rudelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Desailloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Henocque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Brault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Delemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2021.05.004_bib0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2021.05.004_bib0125","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.05.004_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1172-3-17","article-title":"Acromegaly","volume":"3","author":"Chanson","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2021.05.004_bib0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ando.2008.12.011","article-title":"French consensus on the management of acromegaly","volume":"70","author":"Chanson","year":"2009","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2021.05.004_bib0140","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.05.004_bib0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2021.05.004_bib0150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","article-title":"Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly","volume":"23","author":"Kopchick","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2021.05.004_bib0155","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet Lond. Engl"},{"key":"10.1016\/j.ando.2021.05.004_bib0160","article-title":"Somavert [WWW Document]","author":"Anonymous","year":"2018","journal-title":"Eur Med Agency"},{"issue":"Suppl 1","key":"10.1016\/j.ando.2021.05.004_bib0165","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1530\/EJE-09-0333","article-title":"Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY","volume":"161","author":"Brue","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.05.004_bib0170","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ando.2015.10.003","article-title":"Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY","volume":"76","author":"Chanson","year":"2015","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2021.05.004_bib0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.05.004_bib0180","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.05.004_bib0185","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.05.004_bib0190","doi-asserted-by":"crossref","first-page":"e1912869","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of using real-world data to replicate clinical trial evidence","volume":"2","author":"Bartlett","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ando.2021.05.004_bib0195","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","article-title":"Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry","volume":"164","author":"Fieffe","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.05.004_bib0200","doi-asserted-by":"crossref","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.05.004_bib0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12020-020-02501-3","article-title":"Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study","volume":"71","author":"Kuhn","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2021.05.004_bib0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/EJE-16-0956","article-title":"A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues","volume":"176","author":"Franck","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.05.004_bib0215","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","article-title":"Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant","volume":"92","author":"Parkinson","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.05.004_bib0220","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab004","article-title":"Body composition changes with long-term pegvisomant therapy of acromegaly","volume":"5","author":"Kuker","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2021.05.004_bib0225","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2021.05.004_bib0230","series-title":"Advances in patient safety: from research to implementation (Volume 2: Concepts and Methodology), Advances in Patient Safety","article-title":"Clinical inertia and outpatient medical errors","author":"O\u2019Connor","year":"2005"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:25:32Z","timestamp":1762086332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426621000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0003426621000780"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2021.05.004","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients)","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}